DC
PLRX icon

Diametric Capital’s Pliant Therapeutics PLRX Stock Holding History

Diametric Capital’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,463
Closed -$438K – 439
2023
Q1 		$438K Buy
+16,463
New +$469K 0.21% 139

Other funds holding PLRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Diametric Capital's PLRX Position: Q2 2023 in Review

Diametric Capital sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 16,463 shares — an estimated $438K sold.

Diametric Capital first reported a position in PLRX in Q1 2023 and held it in 1 quarter. The position peaked at $438K in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • Diametric Capital reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 16,463 Pliant Therapeutics shares in Q2 2023, an estimated $438K.
  • Diametric Capital first reported a position in Pliant Therapeutics in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Pliant Therapeutics position peaked at $438K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.